I think you're right about the chances of approval once there is efficacy proven.The report states we are spending a lot in the first 12 months after stroke (about $175k per person).
Most of the costs in the table below will be spent regardless of outcome. We are investing a lot in the health response to stroke so a mechanism that can deliver a pay off for patients and their families and potentially get younger people back to work post stroke would be compelling for governments.
Economic cost of stroke 2024 report, page-3
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
76.0¢ |
Change
0.020(2.70%) |
Mkt cap ! $97.35M | |||
| Open | High | Low | Value | Volume |
| 73.5¢ | 76.0¢ | 72.3¢ | $96.97K | 130.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 73.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 76.0¢ | 10000 | 1 |
View Market Depth
| Last trade - 15.40pm 27/09/2024 (20 minute delay) ? |
| AGN (ASX) Chart |